Ficolin-2/A与炎症性疾病
Ficolin-2/A and Inflammatory Diseases
DOI: 10.12677/acm.2026.1651915, PDF,    科研立项经费支持
作者: 施 彤, 张 坤:云南中医药大学基础医学院,云南 昆明;云南省中西医结合慢病防治重点实验室,云南 昆明;田 源, 杨 艳, 王 维, 宋一男*:云南中医药大学基础医学院,云南 昆明
关键词: Ficolin-2/A炎症性疾病固有免疫补体系统巨噬细胞极化Ficolin-2/A Inflammatory Diseases Innate Immunity Complement System Macrophage Polarization
摘要: 慢性炎症性疾病的发生发展与固有免疫紊乱密切相关。Ficolin-2/A作为补体凝集素途径重要模式识别分子,在炎症性疾病中发挥复杂且具有环境依赖性的调控作用。其在呼吸、消化、心血管、自身免疫及肿瘤相关炎症等疾病中表达与功能各异,既可参与宿主防御、减轻病理损伤,也能通过调控巨噬细胞极化、炎症小体活化等途径加重炎症反应,其作用受疾病类型、病理阶段、组织微环境以及激活途径等多种因素影响。目前相关研究在方法学设计、机制解析和临床转化等方面仍存在局限性,深入探究Ficolin-2/A的功能调控机制,可为炎症性疾病的生物标志物筛选与靶向治疗提供新思路。
Abstract: The onset and progression of chronic inflammatory diseases are closely associated with dysregulation of the innate immune system. As a key pattern recognition molecule in the complement-opsonin pathway, Ficolin-2/A plays a complex and context-dependent regulatory role in inflammatory diseases. Its expression and function vary across respiratory, digestive, cardiovascular, autoimmune, and tumor-associated inflammatory diseases. It can participate in host defense and mitigate pathological damage, but it can also exacerbate inflammatory responses by regulating macrophage polarization and inflammasome activation. Its role is influenced by multiple factors, including disease type, pathological stage, tissue microenvironment, and activation pathways. Current research in this field still faces limitations in methodological design, mechanism elucidation, and clinical translation. In-depth investigation of the functional regulatory mechanisms of Ficolin-2/A could provide new insights for biomarker screening and targeted therapy in inflammatory diseases.
文章引用:施彤, 张坤, 田源, 杨艳, 王维, 宋一男. Ficolin-2/A与炎症性疾病[J]. 临床医学进展, 2026, 16(5): 1151-1164. https://doi.org/10.12677/acm.2026.1651915

参考文献

[1] Zhang, R., Xie, Q., Lu, X., Fan, R. and Tong, N. (2024) Research Advances in the Anti-Inflammatory Effects of SGLT Inhibitors in Type 2 Diabetes Mellitus. Diabetology & Metabolic Syndrome, 16, Article No. 99. [Google Scholar] [CrossRef] [PubMed]
[2] Parsons, N., Annamalai, B., Obert, E., Schnabolk, G., Tomlinson, S. and Rohrer, B. (2019) Inhibition of the Alternative Complement Pathway Accelerates Repair Processes in the Murine Model of Choroidal Neovascularization. Molecular Immunology, 108, 8-12. [Google Scholar] [CrossRef] [PubMed]
[3] Ohashi, T. and Erickson, H.P. (1998) Oligomeric Structure and Tissue Distribution of Ficolins from Mouse, Pig and Human. Archives of Biochemistry and Biophysics, 360, 223-232. [Google Scholar] [CrossRef] [PubMed]
[4] Yokota, Y., Arai, T. and Kawasaki, T. (1995) Oligomeric Structures Required for Complement Activation of Serum Mannan-Binding Proteins. Journal of Biochemistry, 117, 414-419. [Google Scholar] [CrossRef] [PubMed]
[5] Yae, Y., Inaba, S., Sato, H., Okochi, K., Tokunaga, F. and Iwanaga, S. (1991) Isolation and Characterization of a Thermolabile β-2 Macroglycoprotein (‘Thermolabile Substance’ or ‘Hakata Antigen’) Detected by Precipitating (Auto) Antibody in Sera of Patients with Systemic Lupus Erythematosus. Biochimica et Biophysica ActaProtein Structure and Molecular Enzymology, 1078, 369-376. [Google Scholar] [CrossRef] [PubMed]
[6] Garlatti, V., Martin, L., Lacroix, M., Gout, E., Arlaud, G.J., Thielens, N.M., et al. (2010) Structural Insights into the Recognition Properties of Human Ficolins. Journal of Innate Immunity, 2, 17-23. [Google Scholar] [CrossRef] [PubMed]
[7] Kilpatrick, D.C. and Chalmers, J.D. (2012) Human L-Ficolin (Ficolin-2) and Its Clinical Significance. Journal of Biomedicine and Biotechnology, 2012, 1-10. [Google Scholar] [CrossRef] [PubMed]
[8] Endo, Y., Sato, Y., Matsushita, M. and Fujita, T. (1996) Cloning and Characterization of the Human Lectin P35 Gene and Its Related Gene. Genomics, 36, 515-521. [Google Scholar] [CrossRef] [PubMed]
[9] Liu, Y., Endo, Y., Homma, S., Kanno, K., Yaginuma, H. and Fujita, T. (2005) Ficolin A and Ficolin B Are Expressed in Distinct Ontogenic Patterns and Cell Types in the Mouse. Molecular Immunology, 42, 1265-1273. [Google Scholar] [CrossRef] [PubMed]
[10] Garred, P., Honoré, C., Ma, Y.J., Rørvig, S., Cowland, J., Borregaard, N., et al. (2010) The Genetics of Ficolins. Journal of Innate Immunity, 2, 3-16. [Google Scholar] [CrossRef] [PubMed]
[11] Ohashi, T. and Erickson, H.P. (1997) Two Oligomeric Forms of Plasma Ficolin Have Differential Lectin Activity. Journal of Biological Chemistry, 272, 14220-14226. [Google Scholar] [CrossRef] [PubMed]
[12] Girija, U.V., Mitchell, D.A., Roscher, S. and Wallis, R. (2011) Carbohydrate Recognition and Complement Activation by Rat Ficolin-B. European Journal of Immunology, 41, 214-223. [Google Scholar] [CrossRef] [PubMed]
[13] Kakinuma, Y., Endo, Y., Takahashi, M., Nakata, M., Matsushita, M., Takenoshita, S., et al. (2003) Molecular Cloning and Characterization of Novel Ficolins from Xenopus laevis. Immunogenetics, 55, 29-37. [Google Scholar] [CrossRef] [PubMed]
[14] Matsushita, M. and Fujita, T. (1992) Activation of the Classical Complement Pathway by Mannose-Binding Protein in Association with a Novel C1s-Like Serine Protease. The Journal of Experimental Medicine, 176, 1497-1502. [Google Scholar] [CrossRef] [PubMed]
[15] Takahashi, M., Iwaki, D., Kanno, K., Ishida, Y., Xiong, J., Matsushita, M., et al. (2008) Mannose-Binding Lectin (MBL)-Associated Serine Protease (MASP)-1 Contributes to Activation of the Lectin Complement Pathway. The Journal of Immunology, 180, 6132-6138. [Google Scholar] [CrossRef] [PubMed]
[16] Takahashi, M., Ishida, Y., Iwaki, D., Kanno, K., Suzuki, T., Endo, Y., et al. (2010) Essential Role of Mannose-Binding Lectin-Associated Serine Protease-1 in Activation of the Complement Factor D. Journal of Experimental Medicine, 207, 29-37. [Google Scholar] [CrossRef] [PubMed]
[17] Matsushita, M., Endo, Y. and Fujita, T. (2013) Structural and Functional Overview of the Lectin Complement Pathway: Its Molecular Basis and Physiological Implication. Archivum Immunologiae et Therapiae Experimentalis, 61, 273-283. [Google Scholar] [CrossRef] [PubMed]
[18] Nauta, A.J., Bottazzi, B., Mantovani, A., Salvatori, G., Kishore, U., Schwaeble, W.J., et al. (2003) Biochemical and Functional Characterization of the Interaction between Pentraxin 3 and C1q. European Journal of Immunology, 33, 465-473. [Google Scholar] [CrossRef] [PubMed]
[19] Wu, Q., Cao, F., Tao, J., Li, X., Zheng, S.G. and Pan, H. (2020) Pentraxin 3: A Promising Therapeutic Target for Autoimmune Diseases. Autoimmunity Reviews, 19, Article 102584. [Google Scholar] [CrossRef] [PubMed]
[20] Gout, E., Moriscot, C., Doni, A., Dumestre-Pérard, C., Lacroix, M., Pérard, J., et al. (2011) M-Ficolin Interacts with the Long Pentraxin PTX3: A Novel Case of Cross-Talk between Soluble Pattern-Recognition Molecules. The Journal of Immunology, 186, 5815-5822. [Google Scholar] [CrossRef] [PubMed]
[21] Le, Y., Lee, S.H., Kon, O.L. and Lu, J. (1998) Human l-Ficolin: Plasma Levels, Sugar Specificity, and Assignment of Its Lectin Activity to the Fibrinogen-Like (FBG) Domain. FEBS Letters, 425, 367-370. [Google Scholar] [CrossRef] [PubMed]
[22] Liu, Y., Endo, Y., Iwaki, D., Nakata, M., Matsushita, M., Wada, I., et al. (2005) Human M-Ficolin Is a Secretory Protein That Activates the Lectin Complement Pathway. The Journal of Immunology, 175, 3150-3156. [Google Scholar] [CrossRef] [PubMed]
[23] Kwon, S., Kim, M., Kim, D., Lee, K., Choi, S., Park, J., et al. (2007) Identification of a Functionally Relevant Signal Peptide of Mouse Ficolin A. BMB Reports, 40, 532-538. [Google Scholar] [CrossRef] [PubMed]
[24] Kuraya, M., Ming, Z., Liu, X., Matsushita, M. and Fujita, T. (2005) Specific Binding of L-Ficolin and H-Ficolin to Apoptotic Cells Leads to Complement Activation. Immunobiology, 209, 689-697. [Google Scholar] [CrossRef] [PubMed]
[25] Brinkmann, C.R., Jensen, L., Dagnæs-Hansen, F., Holm, I.E., Endo, Y., Fujita, T., et al. (2013) Mitochondria and the Lectin Pathway of Complement. Journal of Biological Chemistry, 288, 8016-8027. [Google Scholar] [CrossRef] [PubMed]
[26] 杨一菲. Ficolin-A/2在炎症性肠病中的作用及相关机制研究[D]: [博士学位论文]. 武汉: 武汉大学, 2017.
[27] 丁荃荃. Ficolin-2/A在体内发挥抗肿瘤效应及其激活免疫细胞机制的研究[D]: [博士学位论文]. 武汉: 武汉大学, 2017.
[28] O’Brien, K.L., Wolfson, L.J., Watt, J.P., Henkle, E., Deloria-Knoll, M., McCall, N., et al. (2009) Burden of Disease Caused by Streptococcus Pneumoniae in Children Younger than 5 Years: Global Estimates. The Lancet, 374, 893-902. [Google Scholar] [CrossRef] [PubMed]
[29] Gisch, N., Kohler, T., Ulmer, A.J., Müthing, J., Pribyl, T., Fischer, K., et al. (2013) Structural Reevaluation of Streptococcus Pneumoniae Lipoteichoic Acid and New Insights into Its Immunostimulatory Potency. Journal of Biological Chemistry, 288, 15654-15667. [Google Scholar] [CrossRef] [PubMed]
[30] Gehre, F., Spisek, R., Kharat, A.S., Matthews, P., Kukreja, A., Anthony, R.M., et al. (2009) Role of Teichoic Acid Choline Moieties in the Virulence of Streptococcus pneumoniae. Infection and Immunity, 77, 2824-2831. [Google Scholar] [CrossRef] [PubMed]
[31] Kharat, A.S. and Tomasz, A. (2006) Drastic Reduction in the Virulence of Streptococcus pneumoniae Expressing Type 2 Capsular Polysaccharide but Lacking Choline Residues in the Cell Wall. Molecular Microbiology, 60, 93-107. [Google Scholar] [CrossRef] [PubMed]
[32] Endo, Y., Takahashi, M., Iwaki, D., Ishida, Y., Nakazawa, N., Kodama, T., et al. (2012) Mice Deficient in Ficolin, a Lectin Complement Pathway Recognition Molecule, Are Susceptible to Streptococcus pneumoniae Infection. The Journal of Immunology, 189, 5860-5866. [Google Scholar] [CrossRef] [PubMed]
[33] Vassal-Stermann, E., Lacroix, M., Gout, E., Laffly, E., Pedersen, C.M., Martin, L., et al. (2014) Human L-Ficolin Recognizes Phosphocholine Moieties of Pneumococcal Teichoic Acid. The Journal of Immunology, 193, 5699-5708. [Google Scholar] [CrossRef] [PubMed]
[34] Wu, X., Yao, D., Bao, L., Liu, D., Xu, X., An, Y., et al. (2020) Ficolin a Derived from Local Macrophages and Neutrophils Protects against Lipopolysaccharide-Induced Acute Lung Injury by Activating Complement. Immunology & Cell Biology, 98, 595-606. [Google Scholar] [CrossRef] [PubMed]
[35] Wu, X., Xuan, W., Yang, X., Liu, W., Zhang, H., Jiang, G., et al. (2023) Ficolin a Knockout Alleviates Sepsis-Induced Severe Lung Injury in Mice by Restoring Gut Akkermansia to Inhibit S100A4/STAT3 Pathway. International Immunopharmacology, 121, Article 110548. [Google Scholar] [CrossRef] [PubMed]
[36] Huang, L., Tan, X., Xuan, W., Luo, Q., Xie, L., Xi, Y., et al. (2024) Ficolin-A/2 Aggravates Severe Lung Injury through Neutrophil Extracellular Traps Mediated by Gasdermin D-Induced Pyroptosis. The American Journal of Pathology, 194, 989-1006. [Google Scholar] [CrossRef] [PubMed]
[37] Giraudi, P.J., Salvoza, N., Bonazza, D., Saitta, C., Lombardo, D., Casagranda, B., et al. (2022) Ficolin-2 Plasma Level Assesses Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 23, Article 2813. [Google Scholar] [CrossRef] [PubMed]
[38] Herrscher, C., Roingeard, P. and Blanchard, E. (2020) Hepatitis B Virus Entry into Cells. Cells, 9, Article 1486. [Google Scholar] [CrossRef] [PubMed]
[39] Catanese, M.T., Ansuini, H., Graziani, R., Huby, T., Moreau, M., Ball, J.K., et al. (2010) Role of Scavenger Receptor Class B Type I in Hepatitis C Virus Entry: Kinetics and Molecular Determinants. Journal of Virology, 84, 34-43. [Google Scholar] [CrossRef] [PubMed]
[40] Evans, M.J., von Hahn, T., Tscherne, D.M., Syder, A.J., Panis, M., Wölk, B., et al. (2007) Claudin-1 Is a Hepatitis C Virus Co-Receptor Required for a Late Step in Entry. Nature, 446, 801-805. [Google Scholar] [CrossRef] [PubMed]
[41] Ploss, A., Evans, M.J., Gaysinskaya, V.A., Panis, M., You, H., de Jong, Y.P., et al. (2009) Human Occludin Is a Hepatitis C Virus Entry Factor Required for Infection of Mouse Cells. Nature, 457, 882-886. [Google Scholar] [CrossRef] [PubMed]
[42] Benedicto, I., Molina-Jiménez, F., Bartosch, B., Cosset, F., Lavillette, D., Prieto, J., et al. (2009) The Tight Junction-Associated Protein Occludin Is Required for a Postbinding Step in Hepatitis C Virus Entry and Infection. Journal of Virology, 83, 8012-8020. [Google Scholar] [CrossRef] [PubMed]
[43] Liu, J., Ali, M.A.M., Shi, Y., Zhao, Y., Luo, F., Yu, J., et al. (2009) Specifically Binding of L-Ficolin to N-Glycans of HCV Envelope Glycoproteins E1 and E2 Leads to Complement Activation. Cellular & Molecular Immunology, 6, 235-244. [Google Scholar] [CrossRef] [PubMed]
[44] Hamed, M.R., Brown, R.J.P., Zothner, C., Urbanowicz, R.A., Mason, C.P., Krarup, A., et al. (2014) Recombinant Human L-Ficolin Directly Neutralizes Hepatitis C Virus Entry. Journal of Innate Immunity, 6, 676-684. [Google Scholar] [CrossRef] [PubMed]
[45] Zhao, Y., Ren, Y., Zhang, X., Zhao, P., Tao, W., Zhong, J., et al. (2014) Ficolin-2 Inhibits Hepatitis C Virus Infection, Whereas Apolipoprotein E3 Mediates Viral Immune Escape. The Journal of Immunology, 193, 783-796. [Google Scholar] [CrossRef] [PubMed]
[46] Hu, Y.L., Luo, F.L., Fu, J.L., Chen, T.L., et al. (2013) Early Increased Ficolin-2 Concentrations Are Associated with Severity of Liver Inflammation and Efficacy of Anti-Viral Therapy in Chronic Hepatitis C Patients. Scandinavian Journal of Immunology, 77, 144-150. [Google Scholar] [CrossRef] [PubMed]
[47] Schaffer, T., Schoepfer, A.M. and Seibold, F. (2014) Serum Ficolin-2 Correlates Worse than Fecal Calprotectin and CRP with Endoscopic Crohn’s Disease Activity. Journal of Crohns and Colitis, 8, 1125-1132. [Google Scholar] [CrossRef] [PubMed]
[48] Carbone, F., Valente, A., Perego, C., Bertolotto, M., Pane, B., Spinella, G., et al. (2021) Ficolin-2 Serum Levels Predict the Occurrence of Acute Coronary Syndrome in Patients with Severe Carotid Artery Stenosis. Pharmacological Research, 166, Article 105462. [Google Scholar] [CrossRef] [PubMed]
[49] Formanowicz, D., Gutowska, K. and Formanowicz, P. (2018) Theoretical Studies on the Engagement of Interleukin 18 in the Immuno-Inflammatory Processes Underlying Atherosclerosis. International Journal of Molecular Sciences, 19, Article 3476. [Google Scholar] [CrossRef] [PubMed]
[50] Sprong, T., Jack, D.L., Klein, N.J., Turner, M.W., van der Ley, P., Steeghs, L., et al. (2004) Mannose Binding Lectin Enhances Il-1β and IL-10 Induction by Non-Lipopolysaccharide (LPS) Components of Neisseria Meningitidis. Cytokine, 28, 59-66. [Google Scholar] [CrossRef] [PubMed]
[51] Bi, X., Vitali, C. and Cuchel, M. (2015) ABCA1 and Inflammation: From Animal Models to Humans. Arteriosclerosis, Thrombosis, and Vascular Biology, 35, 1551-1553. [Google Scholar] [CrossRef] [PubMed]
[52] Tumurkhuu, G., Dagvadorj, J., Porritt, R.A., Crother, T.R., Shimada, K., Tarling, E.J., et al. (2018) Chlamydia Pneumoniae Hijacks a Host Autoregulatory IL-1β Loop to Drive Foam Cell Formation and Accelerate Atherosclerosis. Cell Metabolism, 28, 432-448.e4. [Google Scholar] [CrossRef] [PubMed]
[53] Yu, X., Jiang, H., Chen, W., Yin, K., Zhao, G., Mo, Z., et al. (2012) Interleukin-18 and Interleukin-12 Together Downregulate ATP-Binding Cassette Transporter A1 Expression through the Interleukin-18R/Nuclear Factor-κB Signaling Pathway in THP-1 Macrophage-Derived Foam Cells. Circulation Journal, 76, 1780-1791. [Google Scholar] [CrossRef] [PubMed]
[54] Khan, R., Rheaume, E. and Tardif, J. (2018) Examining the Role of and Treatment Directed at IL-1β in Atherosclerosis. Current Atherosclerosis Reports, 20, Article No. 53. [Google Scholar] [CrossRef] [PubMed]
[55] Grebe, A., Hoss, F. and Latz, E. (2018) NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis. Circulation Research, 122, 1722-1740. [Google Scholar] [CrossRef] [PubMed]
[56] Elhage, R., Jawien, J., Rudling, M., Ljunggren, H.G., et al. (2003) Reduced Atherosclerosis in Interleukin-18 Deficient Apolipoprotein E-Knockout Mice. Cardiovascular Research, 59, 234-240. [Google Scholar] [CrossRef] [PubMed]
[57] 刘艾婷. 纤维蛋白胶凝素-2通过上调巨噬细胞NLRP3炎症小体活性促进巨噬细胞泡沫化[D]: [硕士学位论文]. 衡阳: 南华大学, 2020.
[58] Macarie, R.D., Tucureanu, M.M., Ciortan, L., Gan, A., Butoi, E. and Mânduțeanu, I. (2023) Ficolin-2 Amplifies Inflammation in Macrophage-Smooth Muscle Cell Cross-Talk and Increases Monocyte Transmigration by Mechanisms Involving IL-1β and IL-6. Scientific Reports, 13, Article No. 19431. [Google Scholar] [CrossRef] [PubMed]
[59] Fumagalli, S., Perego, C., Zangari, R., De Blasio, D., Oggioni, M., De Nigris, F., et al. (2017) Lectin Pathway of Complement Activation Is Associated with Vulnerability of Atherosclerotic Plaques. Frontiers in Immunology, 8, Article 288. [Google Scholar] [CrossRef] [PubMed]
[60] Cheng, Y., Chen, Y., Sun, X., Li, Y., Huang, C., Deng, H., et al. (2014) Identification of Potential Serum Biomarkers for Rheumatoid Arthritis by High-Resolution Quantitative Proteomic Analysis. Inflammation, 37, 1459-1467. [Google Scholar] [CrossRef] [PubMed]
[61] Zhu, L., Li, Z., Dong, X., Wu, H., Cheng, Y., Xia, S., et al. (2024) Ficolin-A Induces Macrophage Polarization to a Novel Pro-Inflammatory Phenotype Distinct from Classical M1. Cell Communication and Signaling, 22, Article No. 271. [Google Scholar] [CrossRef] [PubMed]
[62] Watanabe, H., Saito, R., Asano, T., Sato, S., Iwadate, H., Kobayashi, H., et al. (2012) Serum L-Ficolin Levels in Patients with Systemic Lupus Erythematosus. Modern Rheumatology, 22, 899-902. [Google Scholar] [CrossRef] [PubMed]
[63] Colliard, S., Jourde-Chiche, N., Clavarino, G., Sarrot-Reynauld, F., Gout, E., Deroux, A., et al. (2018) Autoantibodies Targeting Ficolin-2 in Systemic Lupus Erythematosus Patients with Active Nephritis. Arthritis Care & Research, 70, 1263-1268. [Google Scholar] [CrossRef] [PubMed]
[64] Nisihara, R.M., Magrini, F., Mocelin, V. and Messias-Reason, I.J. (2013) Deposition of the Lectin Pathway of Complement in Renal Biopsies of Lupus Nephritis Patients. Human Immunology, 74, 907-910. [Google Scholar] [CrossRef] [PubMed]
[65] Xie, Y., Liu, F., Wu, Y., Zhu, Y., Jiang, Y., Wu, Q., et al. (2025) Inflammation in Cancer: Therapeutic Opportunities from New Insights. Molecular Cancer, 24, Article No. 51. [Google Scholar] [CrossRef] [PubMed]
[66] Ding, Q., Shen, Y., Li, D., Yang, J., Yu, J., Yin, Z., et al. (2017) Ficolin-2 Triggers Antitumor Effect by Activating Macrophages and CD8+ T Cells. Clinical Immunology, 183, 145-157. [Google Scholar] [CrossRef] [PubMed]
[67] Sica, A. and Mantovani, A. (2012) Macrophage Plasticity and Polarization: In Vivo Veritas. Journal of Clinical Investigation, 122, 787-795. [Google Scholar] [CrossRef] [PubMed]
[68] Larocca, C., Cohen, J.R., Fernando, R.I., Huang, B., Hamilton, D.H. and Palena, C. (2013) An Autocrine Loop between TGF-β1 and the Transcription Factor Brachyury Controls the Transition of Human Carcinoma Cells into a Mesenchymal Phenotype. Molecular Cancer Therapeutics, 12, 1805-1815. [Google Scholar] [CrossRef] [PubMed]
[69] Heldin, C., Vanlandewijck, M. and Moustakas, A. (2012) Regulation of EMT by TGFβ in Cancer. FEBS Letters, 586, 1959-1970. [Google Scholar] [CrossRef] [PubMed]
[70] Padua, D. and Massagué, J. (2009) Roles of TGFβ in Metastasis. Cell Research, 19, 89-102. [Google Scholar] [CrossRef] [PubMed]
[71] Yang, G., Liang, Y., Zheng, T., Song, R., Wang, J., Shi, H., et al. (2016) FCN2 Inhibits Epithelial-Mesenchymal Transition-Induced Metastasis of Hepatocellular Carcinoma via TGF-β/Smad Signaling. Cancer Letters, 378, 80-86. [Google Scholar] [CrossRef] [PubMed]
[72] Liang, J., Pan, Y., Yang, J., Zeng, D. and Li, J. (2025) WNT Signaling in Cancer: Molecular Mechanisms and Potential Therapies. Molecular Biomedicine, 6, Article No. 83. [Google Scholar] [CrossRef